Published in

Public Library of Science, PLoS ONE, 7(8), p. e69064, 2013

DOI: 10.1371/journal.pone.0069064

Links

Tools

Export citation

Search in Google Scholar

NVP-LDE225, a Potent and Selective SMOOTHENED Antagonist Reduces Melanoma Growth In Vitro and In Vivo

Journal article published in 2013 by Ahmad Jalili, Kirsten D. Mertz ORCID, Julia Romanov, Christine Wagner, Frank Kalthoff, Anton Stuetz, Gaurav Pathria, Melanie Gschaider, Georg Stingl, Stephan N. Wagner ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Melanoma is one of the most aggressive cancers and its incidence is increasing worldwide. So far there are no curable therapies especially after metastasis. Due to frequent mutations in members of the mitogen-activated protein kinase (MAPK) signaling pathway, this pathway is constitutively active in melanoma. It has been shown that the SONIC HEDGEHOG (SHH)-GLI and MAPK signaling pathway regulate cell growth in many tumors including melanoma and interact with each other in the regulation of cell proliferation and survival.